Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Reflections upon human cancer immune responsiveness to T cell-based therapy.

Wang E, Tomei S, Marincola FM.

Cancer Immunol Immunother. 2012 Jun;61(6):761-70. doi: 10.1007/s00262-012-1274-9. Epub 2012 May 11. Review.

2.

Tumors as elusive targets of T-cell-based active immunotherapy.

Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S.

Trends Immunol. 2003 Jun;24(6):335-42. Review.

PMID:
12810110
3.

mRNA-based dendritic cell vaccines.

Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K.

Expert Rev Vaccines. 2015 Feb;14(2):161-76. doi: 10.1586/14760584.2014.957684. Epub 2014 Sep 8. Review.

PMID:
25196947
4.
5.

Circumventing immune tolerance through epigenetic modification.

Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM.

Curr Pharm Des. 2010 Jan;16(3):268-76. Review.

PMID:
20109136
6.

T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.

Phan GQ, Wang E, Marincola FM.

Expert Opin Biol Ther. 2001 May;1(3):511-23. Review.

PMID:
11727522
7.

Analysis of vaccine-induced T cells in humans with cancer.

Slezak SL, Worschech A, Wang E, Stroncek DF, Marincola FM.

Adv Exp Med Biol. 2010;684:178-88.

8.

Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity.

Ressing ME, Offringa R, Toes RE, Ossendorp F, de Jong JH, Brandt RM, Kast WM, Melief CJ.

Immunotechnology. 1996 Nov;2(4):241-51. Review.

PMID:
9373306
9.

[Immunotherapy of cancer].

Andersen MH, Schmidt H, Gehl J, von der Maase H, Straten P.

Ugeskr Laeger. 2002 Jun 3;164(23):3008-16. Review. Danish.

PMID:
12082849
10.

Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.

Neeson P, Paterson Y.

Immunol Invest. 2006;35(3-4):359-94. Review.

PMID:
16916758
11.

[Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].

Ikeda H, Shiku H.

Nihon Rinsho. 2012 Dec;70(12):2043-50. Review. Japanese.

PMID:
23259373
12.

Spinning molecular immunology into successful immunotherapy.

Pardoll DM.

Nat Rev Immunol. 2002 Apr;2(4):227-38. Review.

PMID:
12001994
13.

Tumor vaccine: current trends in antigen specific immunotherapy.

Baral R.

Indian J Exp Biol. 2005 May;43(5):389-406. Review.

PMID:
15900903
14.

Cancer vaccines: reborn or just recycled?

Berd D.

Semin Oncol. 1998 Dec;25(6):605-10. Review.

PMID:
9865675
15.

Specificity in cancer immunotherapy.

Schietinger A, Philip M, Schreiber H.

Semin Immunol. 2008 Oct;20(5):276-85. doi: 10.1016/j.smim.2008.07.001. Epub 2008 Aug 5. Review.

16.

Gene-expression profiling in vaccine therapy and immunotherapy for cancer.

Bedognetti D, Wang E, Sertoli MR, Marincola FM.

Expert Rev Vaccines. 2010 Jun;9(6):555-65. doi: 10.1586/erv.10.55. Review.

17.

Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?

Pawelec G.

Cancer Immunol Immunother. 1999 Oct;48(7):343-5. No abstract available.

PMID:
10501845
18.

Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.

Schreiber TH, Raez L, Rosenblatt JD, Podack ER.

Semin Immunol. 2010 Jun;22(3):105-12. doi: 10.1016/j.smim.2010.02.001. Epub 2010 Mar 11. Review.

19.

Immunotherapy: on the edge between experimental and clinical oncology.

Fagnoni FF, Robustelli della Cuna G.

J Chemother. 2001 Feb;13(1):15-23. Review.

PMID:
11233795
20.

Progress in human tumour immunology and immunotherapy.

Rosenberg SA.

Nature. 2001 May 17;411(6835):380-4. Review.

PMID:
11357146

Supplemental Content

Support Center